• Miscellaneous dermatological conditions

Asclera Generic Name & Formulations

General Description

Polidocanol 0.5%, 1%; soln for IV inj; preservative-free.

Pharmacological Class

Sclerosing agent.

How Supplied

Single-use ampules (2mL)—5


Generic Availability


Asclera Indications


To sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1–3mm in diameter) in the lower extremity.

Asclera Dosage and Administration


For IV use only. Spider veins: use 0.5%. Reticular veins: use 1%. Inject soln slowly. Give 0.1–0.3mL per inj; max: 10mL per treatment session. Repeat if necessary; separate sessions by 1–2 weeks. Cover inj site; apply compression bandage or stocking. Have patient walk for 15–20mins after treatment; monitor. Maintain compression (spider veins): 2–3 days; (reticular veins): 5–7 days.


Not established.

Asclera Contraindications


Acute thromboembolic diseases.

Asclera Boxed Warnings

Not Applicable

Asclera Warnings/Precautions


Not studied in varicose veins >3mm in diameter. Do not inject intra-arterially. Monitor for 15–20mins post-inj for anaphylaxis; treat appropriately if occurs. Monitor for venous thrombosis posttreatment. Increased risk of thrombosis in patients with reduced mobility, history of DVT/PE, pregnancy, major surgery within 3mos, prolonged hospitalization. Arterial embolism. Avoid polidocanol foamed with room air. Advise to avoid heavy exercise, sunbathing, long plane flights, hot baths/sauna 2–3 days posttreatment. Pregnancy. Nursing mothers: consider interrupting breastfeeding up to 8hrs after dose.

Asclera Pharmacokinetics

See Literature

Asclera Interactions

Not Applicable

Asclera Adverse Reactions

Adverse Reactions

Mild local reactions at inj site; anaphylaxis (may be fatal).

Asclera Clinical Trials

See Literature

Asclera Note

Not Applicable

Asclera Patient Counseling

See Literature